Published in Thromb Haemost on October 01, 2001
Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev (2013) 1.72
Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci (2008) 1.19
Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency. J Thromb Haemost (2014) 0.93
Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin. J Biol Chem (2010) 0.89
Fibrinolysis and the control of blood coagulation. Blood Rev (2014) 0.86
Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thromb Res (2012) 0.79
Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa. Thromb Haemost (2015) 0.77
Bleeding related to disturbed fibrinolysis. Br J Haematol (2016) 0.76
Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. Haematologica (2009) 0.76
Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis. Blood (2016) 0.75
Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A. Haemophilia (2011) 0.75
Advances and challenges in hemophilic arthropathy. Semin Hematol (2015) 0.75
Images in clinical medicine. Heparin-induced skin necrosis. N Engl J Med (1996) 3.30
CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem (1991) 2.82
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
Ex vivo normothermic machine perfusion and viability testing of discarded human donor livers. Am J Transplant (2013) 2.51
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature (1986) 2.31
Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol (1972) 2.30
Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C. Ann Intern Med (1996) 2.05
The growing number of hemophilia registries: Quantity vs. quality. Clin Pharmacol Ther (2015) 2.04
Idiopathic thrombocytopenic purpura in pregnancy: a randomized trial on the effect of antenatal low dose corticosteroids on neonatal platelet count. Br J Obstet Gynaecol (1990) 2.00
Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med (1995) 1.93
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem (1977) 1.86
Graft-versus-myeloma effect in two cases. Lancet (1996) 1.80
Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost (2007) 1.67
Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest (1978) 1.66
Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Ibalpha and alpha IIb beta 3. J Thromb Haemost (2009) 1.56
Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke (1993) 1.54
Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad Sci U S A (1977) 1.52
Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost (2003) 1.52
Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood (1995) 1.50
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost (2000) 1.49
Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost (2008) 1.48
Articular cartilage is more susceptible to blood induced damage at young than at old age. J Rheumatol (2000) 1.45
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis (1993) 1.45
Factor XI and protection of the fibrin clot against lysis--a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost (1998) 1.43
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost (2000) 1.43
[Withdrawing the use of acetylsalicyclic acid prior to an operation usually not necessary]. Ned Tijdschr Geneeskd (2003) 1.42
How to treat women with antiphospholipid antibodies in pregnancy? Ann Rheum Dis (2001) 1.41
C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa. Thromb Haemost (2001) 1.40
Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up. Haemophilia (2007) 1.40
Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood (1994) 1.39
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost (2000) 1.32
Sequential regulation of the small GTPase Rap1 in human platelets. Mol Cell Biol (2000) 1.32
Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med (1978) 1.30
Combination of a normal D-dimer concentration and a non-high pretest clinical probability score is a safe strategy to exclude deep venous thrombosis. Circulation (2003) 1.28
Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem (1994) 1.27
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia (2002) 1.27
Inactivation of kallikrein in human plasma. J Clin Invest (1983) 1.27
Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med (1978) 1.26
Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res (1974) 1.26
Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost (2001) 1.26
The origin of P-selectin as a circulating plasma protein. Thromb Haemost (1997) 1.25
Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest (1997) 1.23
Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). Blood (1994) 1.21
Chorea in systemic lupus erythematosus and "lupus-like" disease: association with antiphospholipid antibodies. Semin Arthritis Rheum (1987) 1.21
Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest (1998) 1.21
Mutation analysis of patients with Hermansky-Pudlak syndrome: a frameshift hot spot in the HPS gene and apparent locus heterogeneity. Am J Hum Genet (1998) 1.20
Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood (1986) 1.20
Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia (2002) 1.20
Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost (1991) 1.19
Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood (1987) 1.18
The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood (1995) 1.16
Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum (1986) 1.15
Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost (2006) 1.14
Measuring patients' perceptions on their functional abilities: validation of the Haemophilia Activities List. Haemophilia (2006) 1.13
PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS) Eur Heart J (1996) 1.12
Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood (1995) 1.12
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology (2001) 1.11
Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke (1997) 1.11
Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia (2003) 1.10
Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis (1983) 1.10
High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients. Vox Sang (1998) 1.09
Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost (2014) 1.09
Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry (1980) 1.08
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis (1985) 1.07
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet (1999) 1.07
Immunocytochemical localization of fibrinogen, platelet factor 4, and beta thromboglobulin in thin frozen sections of human blood platelets. J Clin Invest (1983) 1.05
Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deficiency: a study of 125 patients of several ethnic backgrounds. J Lab Clin Med (1985) 1.04
Isolation and functional characterization of the active light chain of activated human blood coagulation factor XI. J Biol Chem (1983) 1.04
Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost (1998) 1.03
Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost (1996) 1.03
Binding of factor VIII-von Willebrand factor to human arterial subendothelium precedes increased platelet adhesion and enhances platelet spreading. J Lab Clin Med (1981) 1.02
Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol (2001) 1.02
Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest (1988) 1.01
Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol (2005) 1.01
Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost (2002) 1.00
Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI. J Biol Chem (1978) 0.99
Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor. Biochemistry (1988) 0.99
Immunochemical studies of human high molecular weight kininogen and of its complexes with plasma prekallikrein or kallikrein. J Biol Chem (1980) 0.99
Hepatitis E virus antibodies among patients with hemophilia, blood donors, and hepatitis patients. J Med Virol (1995) 0.99
Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood (1997) 0.98
An intrinsic factor XII- prekallikrein-dependent pathway activates the human plasma renin-angiotensin system. Nature (1979) 0.98
Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost (2005) 0.98
Blood-induced joint damage: a canine in vivo study. Arthritis Rheum (1999) 0.97
The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem (1988) 0.97